Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | GenScript ProBio as well AbTis enter into an Exclusive Worldwide License Agreement for ADC TargetingBy: GenScript ProBio GenScript ProBio is based on the 17-year GenScript R&D and manufacturing expertise and its well-integrated platforms and strong capabilities on the platform have provided the discovery process and anti-protein CDMO services to clients across the world. Additionally, GenScript ProBio has also formed partnerships with three transgenic animal platforms both in the US and overseas, which allows single-stop discovery services for human antibodies using the platform's animals. Dr. Sang Jeon Chung, CEO of AbTis stated, "We are pleased to join forces with GenScript ProBio which is a highly specific CDMO company with deep knowledge and vast knowledge of antibody discovery. We are looking eagerly to work alongside GenScript ProBio to help us create new and exciting anti-drug conjugates to patient benefit and we'll work together to accelerate the process of transformation in pharmaceuticals and help shape the future." Claudin18.2 is currently among the top well-known areas of pharmaceutical research, particularly those working with ADC development. GenScript ProBio team has completed antibody discovery, functional validation, and development of stable cell line (https://www.genscriptprobio.com/ "We are thrilled to collaborate with AbTis and we are honoured to be able to help this exciting antibody-drug conjugate research project," said Dr. Brian Min, CEO of GenScript ProBio. "I believe that this partnership will further demonstrate the advantages of technology and platform for both sides. We look at using GenScript ProBio's extensive CMC development expertise to bring the project on the road to IND and commercialization for the benefit of patients shortly." About GenScript ProBio GenScript ProBio is the Antibody CDMO (https://www.genscriptprobio.com/ Toward the mission of "Innovation through Collaboration" More information: End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|